MTOR and urothelial carcinoma: Additionally, we observe that VWK147 re-sensitizes resistant urothelial carcinoma cells to cisplatin and-in combination with mTOR inhibition-synergistically kills cisplatin-sensitive and -resistant cells, in contrast to what is observed upon treatment with the N-terminal domain-targeting HSP90 inhibitor 17-AAG.